Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + idarubicin + etoposide + daunorubicin
- Development stage
- Unknown
- Lead developer
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This multi-agent chemotherapy regimen, consisting of cytarabine, idarubicin, etoposide, and daunorubicin, is a standardized treatment protocol developed by the Federal Research Institute of Pediatric Hematology, Oncology and Immunology for children with acute myeloid leukemia (AML) and Down Syndrome. The regimen is structured into four distinct chemotherapy blocks: Course 1 (AIE: cytarabine, idarubicin, etoposide), Course 2 (AI: cytarabine, idarubicin), Course 3 (HAD: high-dose cytarabine and daunorubicin), and Course 4 (HA: high-dose cytarabine). This protocol, often referred to as AML-DS-2025 or based on the ML DS 2006 protocol, aims to optimize survival outcomes while minimizing the unique toxicity risks associated with chemotherapy in the Down Syndrome pediatric population by standardizing dose loads and monitoring.
- Other names
- AIE-AI-HAD-HA regimen
02
Targets
DNA polymerase familyDNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cytarabine + idarubicin + etoposide + daunorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + idarubicin + etoposide + daunorubicin.